CRISPR & Cas Genes Market Will Registered 17.03% Growth

Published Date : 31 Mar 2023

The CRISPR & Cas Genes market growth is driven by increasing number of clinical trials associates with CRIPR technology and rising of development of novel technologies. The CRISPR & Cas genes market revenue will reach at USD 8.96 billion by 2030 with a CAGR of around 17.03% from 2022 to 2030.

Market Overview:

With the use of CRISPR and Cas, it is possible to change specific sections of the genome by either adding or eliminating particular DNA sequencing. CRISPR, or clustered regularly interspaced short palindromic repeats, are present in the bacterial genome. In comparison to traditional DNA editing techniques, it is faster and more accurate and offers a wide range of potential applications.

The use of this technology makes altering genes simple and affordable. In biomedical research, genome editing has advanced significantly, paving the way for the future treatment of many genetic and non-genetic diseases. One major factor anticipated to propel the growth of the CRISPR and Cas markets for years to come is the cumulative focus on the development of novel therapies due to the rising pervasiveness of various genetic illnesses and cancer.

Report Highlight:

  • By Product & Service, the global industry has been further divided into products and services based on the two factors of service and product. The product segment, which accounted highest revenue share in 2022, led the market globally. Modern innovations like CRISPR gene editing kits have been created to satisfy the rising need for genome editing solutions. The availability of improved individual items that may be used to do several tasks, including straightforward gene knockouts, selective genome cleavage, fewer off-target cuts, genome editing, and increased specificity, is responsible for the largest revenue share.
  • By Application, biomedical applications will control more than 90% of the market in 2022 among the numerous application segments examined in this research report. The expanded use of CRISPR in biomedical research is what has led to this significant portion of revenue. The sector's sizeable revenue share is primarily due to the growing adoption of CRISPR gene-editing technology across a variety of biological science disciplines. Both the efficacy and specificity of the technology have improved with the development of more efficient delivery mechanisms and nanocarriers.
  • By End-Use, The biotechnology and pharmaceutical industries produced the majority of the market's total revenue. Due to the upcoming clinical applications of CRISPR-Cas9, pharmaceutical start-ups are better equipped than ever to advance products using CRISPR-mediated gene-editing techniques. These technologies are being used more and more by pharmaceutical companies to develop more precise biological models of renal diseases as well as to quickly identify and assess potential therapeutic targets. The market for novel pharmaceuticals created using CRISPR-based gene-editing methods for treating cells and genes is sizable.

CRISPR & Cas Genes Market Report Scope:

Report Coverage Details
Market Size in 2022 USD 2.55 Billion
Projected Forecast Value in 2032 USD 8.96 Billion
Growth Rate 17.03% from 2022 to 2030
Largest Market North America
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered By Product & Service, By Application, an By End-use
Regions Covered North America, Europe, Asia-Pacific, Latin America and Middle East & Africa

Regional Insight:

North America is expected to continue to rule the CRISPR and Cas gene markets over the forecast period. The existence of significant players, rising funding for biotechnology and genomics research, and well-established healthcare infrastructure are just a few of the factors that may be responsible for the market's expansion.

The market is expected to grow faster as a result of favorable government initiatives and increased research collaboration activity, among other factors. Businesses have worked together over time to increase their position in specialized marketplaces for CRISPR and Cas genes. Also, the region has embraced molecular scissors because of the growing market for gene-modified medications in the United States. For instance, in May 2020, the US authorized two CRISPR and Cas-driven gene-editing patents from Merck KGaA.

On the other hand, throughout the prediction period, Asia-Pacific is anticipated to experience the strongest growth. Chinese scientists are gradually learning how to use genome editing to enhance medical treatments, and the country currently holds a significant share of the global CRISPR market. Many CRISPR-based clinical trials have been established, mainly for the treatment of cancer. Government spending on research and development (R&D) is rising in China and Japan, which is helping to accelerate the development of novel medicines. For instance, For instance, the Japanese biotech business Setsuro Tech received a patent for CRISPR-Cas9 technology from Dublin-based ERS Genomics in March 2021.

Market Dynamics:


Increasing Use of CRISPR technology in genetic disease research

Genome editing makes it easier to develop more precise cellular and animal models of disease processes, which increases our understanding of how genetics contributes to diagnostics. Techniques for modifying the genome are being explored as potentially effective methods for human gene therapy.

Research on genetic disorders is increasingly using CRISPR technology. The use of CRISPR-Cas systems in bacterial activity, an increase in government investment in genome editing research and development, and the use of CRISPR technology to boost crop productivity have been the main drivers of the global demand for CRISPR and Cas systems.


Growing ethical and security concerns with the use of CRISPR and cas genes in therapy

The commercialization of CRISPR and Cas genes will be hampered in the future by growing ethical and safety concerns about gene editing and the creation of GM foods and organisms.  The modification of human gremlins raises the most ethical questions regarding CRISPR technology. Human error-prone genes can be altered using CRISPR technology to address several disorders. The use of CRISPR technology to alter human natural DNA has significant ethical implications. However, according to a statement from the US National Institutes of Health, no funding is provided for any research using genome editing technologies due to ethical concerns.


Continuous improvements to the CRISPR and Cas Gene systems

Modern advancements in biotechnology have made it conceivable for CRISPR and Cas gene systems to be used broadly, directly or indirectly, for improvements to human health.  Somatic gene editing, which helps change a person's DNA, is used to treat various disorders, including sickle cell disease, HIV, amyloidosis, and many others. It is predicted that, for different types of cancer, this therapy is one of the most advanced therapies.

Cancer research is undergoing a revolution as a result of recent advances in the CRISPR and Cas systems. The growth in advanced technologies such as newborn screening, karyotyping, and others increases the demand for gene editing techniques such as CRISPR and Cas gene technology, and the biotechnological sector increases the utilization of this technology to enhance the quality of agricultural production through inventive breeding techniques.


Utilizing the CRISPR gene is expensive and the availability of alternative

The cost of using CRISPR genes is too high, which will impede market growth over the projection period. Its usage in drug discovery and pharmaceutical research and development is hindered by the fact that it is an expensive and time-consuming technique. The expense of adopting this technology is also rising due to a scarcity of expertise.

Recent Developments:

  • March 2021, AmpSeq CRISPR Analysis System, developed by ntegrated DNA Technologies, provides end-to-end solutions for assessing the whole range of on- and off-target genome editing outcomes in CRISPR research projects.
  • December 2020, Preclinical findings in support of NTLA-5001, the company’s wholly-owned Wilms’ Tumor 1 (WT1)-directed T cell receptor (TCR)-T cell therapy candidate for the treatment of acute myeloid leukemia, were released by Intellia Therapeutics, Inc. (AML).

Major Key Players:

  • Caribou Biosciences, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Cellectis
  • AstraZeneca
  • Editas Medicine, Inc.
  • Addgene
  • Egenesis
  • Horizon Discovery Group Plc
  • Intellia Therapeutics, Inc.
  • Genscrip
  • Danaher Corporation
  • Lonza
  • Merck KGaA
  • Synthego
  • Mammoth Biosciences
  • Inscripta, Inc.
  • Cibus
  • New England BioLabs
  • Takara Bio, Inc.

Market Segmentation:

By Product & Service

  • By Service
    • Microbial Gene Editing
    • Cell Line Engineering
    • gRNA Design
    • DNA Synthesis
  • By Product
    • Design Tool
    • Kits & Enzymes
    • Libraries
    • Antibodies
    • Others

By Application

  • Agricultural
  • Biomedical
    • Functional Genomics
    • Genome Engineering
    • Disease Model Studies
    • Epigenetics
    • Others

By End-Use

  • Contract Research Organizations (CROs),
  • Academics & Government Research Institutes
  • Biotechnology & Pharmaceutical Companies

Buy this Research Report@

You can place an order or ask any questions, please feel free to contact at| +1 9197 992 333